Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.37 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.37 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.35 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.35 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.35 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL634352 | 0.85 | TYR (0.41) | MEN1KMT2AALDH1A1GUCY1B2GUCY1A2 | |
| SCHEMBL15162641 | 0.82 | CACNA1G (0.38) | MEN1KMT2AALDH1A1CACNA1GCACNA1H | |
| SCHEMBL3440072 | 0.79 | PTPN1 (0.42) | MEN1KMT2AALDH1A1CACNA1GCACNA1H | |
| SCHEMBL12468720 | 0.79 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1SMN1; SMN2NR1H2 | |
| SCHEMBL2116090 | 0.79 | CACNA1G (0.31) | MEN1KMT2AALDH1A1CACNA1GCACNA1H | |
| SCHEMBL15177607 | 0.76 | MEN1 (0.43) | MEN1KMT2AALDH1A1CACNA1GCACNA1H | |
| SCHEMBL15154646 | 0.75 | ALDH1A1 (0.36) | MEN1KMT2AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL2115672 | 0.74 | CACNA1G (0.47) | ALDH1A1CACNA1GCACNA1HCACNA1INPC1 | |
| SCHEMBL634950 | 0.73 | ALDH1A1 (0.63) | MEN1KMT2AALDH1A1CACNA1GCACNA1H | |
| SCHEMBL696460 | 0.73 | CYP19A1 (0.45) | MEN1KMT2ANR1H2NR1H3P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524750-B2 | (Pyrazol-3-yl)-1,3,4-thiadiazol-2-amine and (pyrazol-3-yl)-1,3,4-thiazol-2-amine compounds | GLAXO GROUP LIMITED (GB) | 2013-09-03 | — | — | US | disclosed |
| US-8524750-B2 | (Pyrazol-3-yl)-1,3,4-thiadiazol-2-amine and (pyrazol-3-yl)-1,3,4-thiazol-2-amine compounds | GLAXO GROUP LIMITED (GB) | 2013-09-03 | — | — | US | disclosed |
| US-8524750-B2 | (Pyrazol-3-yl)-1,3,4-thiadiazol-2-amine and (pyrazol-3-yl)-1,3,4-thiazol-2-amine compounds | GLAXO GROUP LIMITED (GB) | 2013-09-03 | — | — | US | disclosed |
| EP-2419426-B1 | (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS | GLAXO GROUP LTD (GB) | 2013-08-14 | — | — | EP | disclosed |
| EP-2419426-B1 | (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS | GLAXO GROUP LTD (GB) | 2013-08-14 | — | — | EP | disclosed |
| US-20120095064-A1 | (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20120095064-A1 | (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20120095064-A1 | (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| WO-2010118852-A1 | ( PYRAZOL-3-YL) -1, 3, 4-THIADIAZOL-2-AMINE AND ( PYRAZOL-3-YL) -1, 3, 4-THIAZOL-2-AMINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095064-A1 | (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS | H1-3, CHRM2, TBL3 | MEN1 564/4885KMT2A 2219/4885ALDH1A1 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.